Latest Healthcare Research Reports

Tag: rare disease diagnostics market

  • Rare Disease Diagnostics Market Industry Outlook 2026–2030 Highlighting Growth Momentum And Market Trends

    Rare Disease Diagnostics Market Industry Outlook 2026–2030 Highlighting Growth Momentum And Market Trends

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Increase In Market Value Is Predicted For The Rare Disease Diagnostics Market During The 2026–2030 Period?

    The rare disease diagnostics market has demonstrated strong growth in recent years. This market is set to expand from $38.14 billion in 2025 to $41.91 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. The growth observed in prior periods can be attributed to the wider availability of genetic testing, increased awareness of rare diseases among medical professionals, a rise in the application of molecular diagnostics, the proliferation of specialized diagnostic laboratories, and enhanced access to advanced imaging technologies.

    The rare disease diagnostics market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $62.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. Several factors are expected to drive this growth throughout the forecast period, including the increasing acceptance of personalized medicine, augmented investments in genomics research, a heightened need for the early detection of rare diseases, the expanded integration of AI-powered diagnostic instruments, and the broadened scope of rare disease screening initiatives. Key trends anticipated during this period encompass the greater embrace of next-generation sequencing diagnostics, the increasing application of multi-gene panel testing, the deeper incorporation of sophisticated imaging techniques in rare disease diagnosis, the establishment of more centralized rare disease testing facilities, and a stronger emphasis on prompt and precise diagnosis.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    Which Growth Factors Are Strengthening The Rare Disease Diagnostics Market Landscape?

    The increasing prevalence of rare diseases is projected to fuel the expansion of the rare disease diagnostics market. Rare diseases are medical conditions that affect a small portion of the population compared to more common illnesses, often requiring specific diagnostic tools for early and accurate detection. Rare disease diagnostics are instrumental in improving disease management, enabling the identification of potential therapeutics, and reducing unneeded or harmful treatments, thus fostering more effective patient care. For instance, in March 2025, according to Kidney Research UK, an UK-based kidney disease charity, the rare kidney disease landscape currently includes over 150 distinct conditions, impacting an estimated 70 per 100,000 people, predominantly originating from genetic alterations. Therefore, the rise in rare disease incidence is a primary driver for the growth of the rare disease diagnostics market.

    How Does Segment Analysis Break Down The Rare Disease Diagnostics Market Structure?

    The rare disease diagnostics market covered in this report is segmented –

    1) By Test Type: Genetic Test, General Lab Test, Imaging Test

    2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

    4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

    5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

    2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

    What Trends Are Influencing The Future Of The Rare Disease Diagnostics Market?

    Companies operating within the rare disease community app market are concentrating on developing advanced solutions, such as natural language processing (NLP) analytics, to enhance patient engagement, streamline communication with healthcare providers, and bolster disease-management support. Natural language processing (NLP) analytics refers to artificial intelligence-driven methodologies that analyze, interpret, and condense human language to generate actionable health insights for patients and clinicians. For example, in December 2024, Know Rare, Inc., a UK-based health technology company, launched the HealthStoryAI app. This app includes AI-generated summaries of patient-reported experiences, structured symptom and daily health tracking, and personalized insight dashboards, which collectively aid patients and healthcare providers in identifying meaningful health patterns and empowering individuals with rare diseases to better manage their conditions.

    Who Are The Businesses Driving Activity In The Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

    Access The Complete Rare Disease Diagnostics Market Report:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Which Region Contributes The Most To The Rare Disease Diagnostics Market?

    North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Rare Disease Diagnostics Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company

    Rare Disease Diagnostics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Diseases Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Inflammatory Disease Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rising incidence and improved diagnostics are transforming the rare disease diagnostics market

    Rising incidence and improved diagnostics are transforming the rare disease diagnostics market

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    From Its 2026 Market Size, What Value Is The Rare Disease Diagnostics Market Projected To Reach By 2030?

    The rare disease diagnostics market has experienced significant expansion recently. This market is projected to expand from $38.14 billion in 2025 to $41.91 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. Historical expansion has been driven by factors such as the broader availability of genetic testing, enhanced recognition of rare diseases among medical professionals, the expanded application of molecular diagnostics, the proliferation of specialized diagnostic laboratories, and better access to sophisticated imaging technologies.

    The rare disease diagnostics market size is anticipated to undergo significant growth in the coming years. Its value is projected to climb to $62.18 billion in 2030, displaying a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period can be attributed to the wider adoption of personalized medicine, increasing investments in genomics research, a rising need for early-stage rare disease detection, the greater integration of AI-driven diagnostic tools, and the broadening of rare disease screening programs. Noteworthy trends in the forecast period encompass the increasing embrace of next-generation sequencing diagnostics, a growing utilization of multi-gene panel testing, the expanding integration of advanced imaging in rare disease diagnosis, the establishment of more centralized rare disease testing centers, and a heightened focus on early and accurate diagnosis.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    Which Key Factors Are Driving The Rare Disease Diagnostics Market Growth?

    A rise in the occurrence of rare diseases is projected to drive the expansion of the rare disease diagnostics market in the future. These conditions are health issues impacting a minor segment of the populace compared to widespread illnesses, frequently necessitating specialized diagnostic instruments for prompt and precise identification. Diagnostics for rare diseases contribute to better disease management, facilitate the discovery of potential therapies, and minimize needless or detrimental treatments, ultimately fostering more effective patient care. As an example, in March 2025, Kidney Research UK, an UK-based kidney disease charity, stated that the current scope of rare kidney diseases encompasses more than 150 distinct conditions, impacting approximately 70 per 100,000 people, primarily stemming from genetic changes. Consequently, the growing frequency of rare diseases is fueling the expansion of the rare disease diagnostics market.

    How Is The Rare Disease Diagnostics Market Organized By Segment Classification?

    The rare disease diagnostics market covered in this report is segmented –

    1) By Test Type: Genetic Test, General Lab Test, Imaging Test

    2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

    4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

    5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

    2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

    Which Trends Are Guiding The Direction Of The Rare Disease Diagnostics Market?

    Leading companies in the rare disease diagnostics market are prioritizing the development of advanced solutions, such as high-sensitivity whole genome sequencing (WGS) platforms. Their goal is to enhance diagnostic precision, expand the scope of variant detection, and accelerate the identification of complex rare disorders. High-sensitivity WGS platforms allow for a comprehensive analysis of nearly all disease-causing genetic variants in a single test, thus facilitating earlier and more accurate diagnoses. For example, in April 2023, Centogene GmbH, a rare disease company from Germany, introduced CentoGenome. This enhanced next-generation sequencing (NGS)-based whole genome sequencing solution is tailored for the diagnosis of rare and neurodegenerative diseases. The platform provides broad variant coverage, which includes Copy Number Variations (CNVs) linked to spinal muscular atrophy (SMA) and intricate pathogenic variants associated with Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome integrates PCR-free technology to minimize sequencing bias in challenging genomic regions. This feature ensures higher-quality data and deeper insights into coding, regulatory, and intronic areas, thereby supporting more precise clinical interpretation.

    Who Are The Industry Participants Involved In The Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

    Get The Full Rare Disease Diagnostics Market Report:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Which Region Leads The Rare Disease Diagnostics Market In Overall Market Size?

    North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Rare Disease Diagnostics Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company

    Rare Disease Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Diseases Treatment Market Report

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Inflammatory Disease Treatment Market Report

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rare Disease Diagnostics Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

    Rare Disease Diagnostics Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Valuation Is Forecasted For The Rare Disease Diagnostics Market By 2030 Starting From Its 2026 Size?

    The rare disease diagnostics market size has experienced robust growth in recent years. It is projected to expand from $38.14 billion in 2025 to $41.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. The historical growth in this market can be attributed to the expansion of genetic testing availability, rising awareness of rare diseases among clinicians, increasing use of molecular diagnostics, growth of specialized diagnostic laboratories, and improved access to advanced imaging technologies.

    The rare disease diagnostics market is projected to experience substantial expansion in the coming years, reaching a valuation of $62.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. This anticipated growth over the forecast period is propelled by factors such as the wider adoption of personalized medicine, increased investment in genomics research, a heightened need for early detection of rare diseases, the growing incorporation of AI-powered diagnostic instruments, and the expansion of rare disease screening initiatives. Key trends anticipated during this period encompass the increasing uptake of next-generation sequencing diagnostics, a surge in the application of multi-gene panel testing, the growing integration of advanced imaging technologies for rare disease diagnosis, the establishment of more centralized rare disease testing facilities, and a sharpened emphasis on prompt and precise diagnosis.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    Which Market Drivers Are Supporting The Expansion Of The Rare Disease Diagnostics Market?

    The future expansion of the rare disease diagnostics market is anticipated to be driven by the rising occurrence of rare diseases. These health conditions, which affect a small proportion of the population compared to more common diseases, frequently necessitate specialized diagnostic tools for early and accurate detection. Rare disease diagnostics help improve disease management, enable the identification of potential therapeutics, and reduce unnecessary or harmful treatments, thereby supporting more effective patient care. To illustrate, in March 2025, Kidney Research UK, an UK-based kidney disease charity, stated that the current rare kidney disease landscape includes over 150 distinct conditions, affecting an estimated 70 per 100,000 people, predominantly arising from genetic alterations. Consequently, the heightened incidence of rare diseases is fueling the growth of the rare disease diagnostics market.

    Which Segment Categories Define The Rare Disease Diagnostics Market?

    The rare disease diagnostics market covered in this report is segmented –

    1) By Test Type: Genetic Test, General Lab Test, Imaging Test

    2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

    4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

    5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

    2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

    What Trends Are Projected To Affect The Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market are prioritizing the creation of advanced solutions, including high-sensitivity whole genome sequencing (WGS) platforms, to elevate diagnostic precision, expand the scope of variant detection, and accelerate the identification of complex rare disorders. These high-sensitivity WGS platforms allow for a comprehensive analysis of nearly all disease-causing genetic variants in a single test, thereby supporting earlier and more accurate diagnoses. For instance, in April 2023, Centogene GmbH, a Germany-based rare disease company, launched CentoGenome, an improved next-generation sequencing (NGS)-based whole genome sequencing solution tailored for the diagnosis of rare and neurodegenerative diseases. The platform offers broad variant coverage, encompassing Copy Number Variations (CNVs) associated with spinal muscular atrophy (SMA) and intricate pathogenic variants connected to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome incorporates PCR-free technology to mitigate sequencing bias in difficult genomic regions, facilitating higher-quality data and deeper insight into coding, regulatory, and intronic areas to support more precise clinical interpretation.

    Who Are The Top Companies Competing In The Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

    Read the full rare disease diagnostics market report here:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    How Is The Rare Disease Diagnostics Market Distributed Across Key Geographic Regions?

    North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Rare Disease Diagnostics Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company

    Rare Disease Diagnostics Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Diseases Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Inflammatory Disease Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rare Disease Diagnostics Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

    Rare Disease Diagnostics Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Valuation Is Forecasted For The Rare Disease Diagnostics Market By 2030 Starting From Its 2026 Size?

    The rare disease diagnostics market size has experienced robust growth in recent years. It is projected to expand from $38.14 billion in 2025 to $41.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. The historical growth in this market can be attributed to the expansion of genetic testing availability, rising awareness of rare diseases among clinicians, increasing use of molecular diagnostics, growth of specialized diagnostic laboratories, and improved access to advanced imaging technologies.

    The rare disease diagnostics market is projected to experience substantial expansion in the coming years, reaching a valuation of $62.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. This anticipated growth over the forecast period is propelled by factors such as the wider adoption of personalized medicine, increased investment in genomics research, a heightened need for early detection of rare diseases, the growing incorporation of AI-powered diagnostic instruments, and the expansion of rare disease screening initiatives. Key trends anticipated during this period encompass the increasing uptake of next-generation sequencing diagnostics, a surge in the application of multi-gene panel testing, the growing integration of advanced imaging technologies for rare disease diagnosis, the establishment of more centralized rare disease testing facilities, and a sharpened emphasis on prompt and precise diagnosis.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    Which Market Drivers Are Supporting The Expansion Of The Rare Disease Diagnostics Market?

    The future expansion of the rare disease diagnostics market is anticipated to be driven by the rising occurrence of rare diseases. These health conditions, which affect a small proportion of the population compared to more common diseases, frequently necessitate specialized diagnostic tools for early and accurate detection. Rare disease diagnostics help improve disease management, enable the identification of potential therapeutics, and reduce unnecessary or harmful treatments, thereby supporting more effective patient care. To illustrate, in March 2025, Kidney Research UK, an UK-based kidney disease charity, stated that the current rare kidney disease landscape includes over 150 distinct conditions, affecting an estimated 70 per 100,000 people, predominantly arising from genetic alterations. Consequently, the heightened incidence of rare diseases is fueling the growth of the rare disease diagnostics market.

    Which Segment Categories Define The Rare Disease Diagnostics Market?

    The rare disease diagnostics market covered in this report is segmented –

    1) By Test Type: Genetic Test, General Lab Test, Imaging Test

    2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

    4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

    5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

    2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

    What Trends Are Projected To Affect The Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market are prioritizing the creation of advanced solutions, including high-sensitivity whole genome sequencing (WGS) platforms, to elevate diagnostic precision, expand the scope of variant detection, and accelerate the identification of complex rare disorders. These high-sensitivity WGS platforms allow for a comprehensive analysis of nearly all disease-causing genetic variants in a single test, thereby supporting earlier and more accurate diagnoses. For instance, in April 2023, Centogene GmbH, a Germany-based rare disease company, launched CentoGenome, an improved next-generation sequencing (NGS)-based whole genome sequencing solution tailored for the diagnosis of rare and neurodegenerative diseases. The platform offers broad variant coverage, encompassing Copy Number Variations (CNVs) associated with spinal muscular atrophy (SMA) and intricate pathogenic variants connected to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome incorporates PCR-free technology to mitigate sequencing bias in difficult genomic regions, facilitating higher-quality data and deeper insight into coding, regulatory, and intronic areas to support more precise clinical interpretation.

    Who Are The Top Companies Competing In The Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

    Read the full rare disease diagnostics market report here:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    How Is The Rare Disease Diagnostics Market Distributed Across Key Geographic Regions?

    North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Rare Disease Diagnostics Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company

    Rare Disease Diagnostics Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Diseases Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Inflammatory Disease Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rare Disease Diagnostics Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

    Rare Disease Diagnostics Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Valuation Is Forecasted For The Rare Disease Diagnostics Market By 2030 Starting From Its 2026 Size?

    The rare disease diagnostics market size has experienced robust growth in recent years. It is projected to expand from $38.14 billion in 2025 to $41.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. The historical growth in this market can be attributed to the expansion of genetic testing availability, rising awareness of rare diseases among clinicians, increasing use of molecular diagnostics, growth of specialized diagnostic laboratories, and improved access to advanced imaging technologies.

    The rare disease diagnostics market is projected to experience substantial expansion in the coming years, reaching a valuation of $62.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. This anticipated growth over the forecast period is propelled by factors such as the wider adoption of personalized medicine, increased investment in genomics research, a heightened need for early detection of rare diseases, the growing incorporation of AI-powered diagnostic instruments, and the expansion of rare disease screening initiatives. Key trends anticipated during this period encompass the increasing uptake of next-generation sequencing diagnostics, a surge in the application of multi-gene panel testing, the growing integration of advanced imaging technologies for rare disease diagnosis, the establishment of more centralized rare disease testing facilities, and a sharpened emphasis on prompt and precise diagnosis.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    Which Market Drivers Are Supporting The Expansion Of The Rare Disease Diagnostics Market?

    The future expansion of the rare disease diagnostics market is anticipated to be driven by the rising occurrence of rare diseases. These health conditions, which affect a small proportion of the population compared to more common diseases, frequently necessitate specialized diagnostic tools for early and accurate detection. Rare disease diagnostics help improve disease management, enable the identification of potential therapeutics, and reduce unnecessary or harmful treatments, thereby supporting more effective patient care. To illustrate, in March 2025, Kidney Research UK, an UK-based kidney disease charity, stated that the current rare kidney disease landscape includes over 150 distinct conditions, affecting an estimated 70 per 100,000 people, predominantly arising from genetic alterations. Consequently, the heightened incidence of rare diseases is fueling the growth of the rare disease diagnostics market.

    Which Segment Categories Define The Rare Disease Diagnostics Market?

    The rare disease diagnostics market covered in this report is segmented –

    1) By Test Type: Genetic Test, General Lab Test, Imaging Test

    2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

    4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

    5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

    2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

    What Trends Are Projected To Affect The Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market are prioritizing the creation of advanced solutions, including high-sensitivity whole genome sequencing (WGS) platforms, to elevate diagnostic precision, expand the scope of variant detection, and accelerate the identification of complex rare disorders. These high-sensitivity WGS platforms allow for a comprehensive analysis of nearly all disease-causing genetic variants in a single test, thereby supporting earlier and more accurate diagnoses. For instance, in April 2023, Centogene GmbH, a Germany-based rare disease company, launched CentoGenome, an improved next-generation sequencing (NGS)-based whole genome sequencing solution tailored for the diagnosis of rare and neurodegenerative diseases. The platform offers broad variant coverage, encompassing Copy Number Variations (CNVs) associated with spinal muscular atrophy (SMA) and intricate pathogenic variants connected to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome incorporates PCR-free technology to mitigate sequencing bias in difficult genomic regions, facilitating higher-quality data and deeper insight into coding, regulatory, and intronic areas to support more precise clinical interpretation.

    Who Are The Top Companies Competing In The Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

    Read the full rare disease diagnostics market report here:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    How Is The Rare Disease Diagnostics Market Distributed Across Key Geographic Regions?

    North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Rare Disease Diagnostics Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company

    Rare Disease Diagnostics Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Diseases Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Inflammatory Disease Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rare Disease Diagnostics Market Future Outlook: Strong Growth Expected Toward $62.18 Billion by 2030

    Rare Disease Diagnostics Market Future Outlook: Strong Growth Expected Toward $62.18 Billion by 2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the rare disease diagnostics market from 2026–2035 with trusted insights from The Business Research Company

    What is the estimated market size of the Rare Disease Diagnostics Market by the end of 2030?

    The rare disease diagnostics market has experienced substantial expansion over recent years. It is projected to grow from $38.14 billion in 2025 to $41.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.9%. This historical growth can be ascribed to the broader availability of genetic testing, increasing awareness of rare diseases among clinicians, the rising application of molecular diagnostics, the proliferation of specialized diagnostic laboratories, and enhanced access to advanced imaging technologies.

    The rare disease diagnostics market is projected to experience substantial expansion in the next few years, with its size anticipated to reach $62.18 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period is primarily fueled by the increasing adoption of personalized medicine, rising investments in genomics research, a growing demand for the early detection of rare diseases, the increasing integration of AI-driven diagnostic tools, and the broadening scope of rare disease screening programs. Furthermore, key trends anticipated in this period encompass the increasing adoption of next-generation sequencing diagnostics, a rising utilization of multi-gene panel testing, the growing integration of advanced imaging in rare disease diagnosis, the expansion of centralized rare disease testing centers, and an enhanced focus on achieving early and accurate diagnoses.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    What Drivers Are Shaping Future Opportunities In The Rare Disease Diagnostics Market?

    The rare disease diagnostics market is projected to grow as a result of the escalating occurrence of rare diseases. These are health conditions impacting a minor fraction of individuals compared to more widespread ailments, frequently demanding specialized diagnostic tools for early and accurate detection. Rare disease diagnostics are instrumental in improving how diseases are managed, enabling the identification of potential therapeutics, and reducing unnecessary or harmful treatments, thereby fostering more effective patient care. For instance, in March 2025, according to Kidney Research UK, an UK-based kidney disease charity, currently, the rare kidney disease landscape includes over 150 distinct conditions, affecting an estimated 70 per 100,000 people, predominantly arising from genetic alterations. Therefore, the surge in rare disease incidence is driving the growth of the rare disease diagnostics market.

    Which Segments Are Gaining Traction In The Rare Disease Diagnostics Market?

    The rare disease diagnostics market covered in this report is segmented –

    1) By Test Type: Genetic Test, General Lab Test, Imaging Test

    2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

    4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

    5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

    2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

    Which Trends Are Expected To Influence The Rare Disease Diagnostics Market In The Upcoming Years?

    Leading firms within the rare disease diagnostics market are concentrating on creating sophisticated solutions, like advanced high-sensitivity whole genome sequencing (WGS) platforms, aiming to enhance diagnostic accuracy, broaden the scope of variant detection, and expedite the discovery of intricate rare conditions. These high-sensitivity WGS platforms facilitate an extensive examination of almost all genetic variants responsible for diseases through one test, thus promoting quicker and more precise diagnoses. As an illustration, in April 2023, Centogene GmbH, a German rare disease specialist, introduced CentoGenome. This product is an advanced next-generation sequencing (NGS)-based whole genome sequencing solution specifically engineered for identifying rare and neurodegenerative diseases. The CentoGenome platform provides extensive variant coverage, encompassing Copy Number Variations (CNVs) relevant to spinal muscular atrophy (SMA) and intricate pathogenic variants connected to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Furthermore, CentoGenome integrates PCR-free technology, which helps mitigate sequencing bias in challenging genomic areas, resulting in superior data quality and more profound understanding of coding, regulatory, and intronic regions for improved clinical interpretation.

    Who Are The Top-Performing Companies In The Rare Disease Diagnostics Market In Recent Years?

    Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Which Region Currently Holds The Largest Share Of The Rare Disease Diagnostics Market?

    North America was the largest region in the rare disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Rare Disease Diagnostics Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2026, By The Business Research Company

    Rare Kidney Diseases Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

    Rare Diseases Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Clinical Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Which Emerging Trends Are Driving The Rare Disease Diagnostics Market Toward $56.08 Billion By 2029?

    Which Emerging Trends Are Driving The Rare Disease Diagnostics Market Toward $56.08 Billion By 2029?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What CAGR And Valuation Are Anticipated For The Rare Disease Diagnostics Market?

    In recent times, there has been a substantial growth in the market size for rare disease diagnostics. The market is anticipated to expand from $35.23 billion in 2024 to $38.14 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this growth during the historic period include the increased need for cloud-based diagnostics, a heightened focus on enhancing efficiency, a rise in neurological disease instances, a surge in immunological disorders, and a boost to healthcare expenditure.

    In the next several years, the market for rare disease diagnostics is projected to exhibit considerable growth, reaching a valuation of $56.08 billion in 2029 with a compound annual growth rate (CAGR) of 10.1%. Factors contributing to this growth during the forecast period include the rising incidence of rare diseases, enhanced government initiatives, an increase in the number of hospitals and diagnostic laboratories, the growth of hematology diseases, and improvements in healthcare infrastructure. The time frame for the forecast also entails significant developments in genetic testing technologies, the inception of whole-genome sequencing and next-generation sequencing (NGS), comprehensive financial investments, and strategic partnerships for research endeavors.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    What Core Drivers Are Expected To Influence The Rare Disease Diagnostics Market?

    The rise in the occurrence of rare diseases is predicted to stimulate the expansion of the rare disease diagnostics market in future. A rare disease is a health problem with a low prevalence rate, affecting a minuscule number of people compared to other common diseases within the population. Diagnostics for rare diseases play a crucial role in disease management, identifying potential therapies, and avoiding treatments that could lead to severe side effects, thereby aiding in effective therapy. To illustrate, Health Match, an Australian digital health firm, reported in November 2022 that there are about 150 rare kidney conditions that occur quite frequently globally, with 60–80 cases per 100,000 individuals in the US and Europe. Hence, the escalating rate of rare diseases is bolstering the development of the rare disease diagnostics market.

    What Are The Main Segment Classifications In The Rare Disease Diagnostics Market?

    The rare disease diagnosticsmarket covered in this report is segmented –

    1) By Test Type: Genetic Test; General Lab Test; Imaging Test

    2) By Technology: Capillary Sequencing; Whole Genome Sequencing; Whole Exome Sequencing; Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample; Buccal Swab Sample; Blood; Saliva

    4) By Disease Type: Gastroenterology Disease; Endocrine And Metabolism Disorders Disease; Hematology And Oncology Disease; Dermatology Disease; Cardiovascular Disorders; Neurology Disease

    5) By End User: Hospital Laboratories; Diagnostics Laboratories; Genetic Testing Laboratories; Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing; Targeted Gene Panels; Exome Sequencing; Carrier Testing

    2) By General Lab Test: Blood Tests; Biochemical Assays; Urine Tests; Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging); CT (Computed Tomography) Scans; Ultrasound; X-Rays

    How Are Industry Trends Steering The Expansion Of The Rare Disease Diagnostics Market?

    The rare disease diagnostics market is witnessing a significant trend in the form of technological advancements. To maintain their market position, prominent firms in the market are embracing these cutting-edge technologies. For example, in April 2023, Centogene GmbH, a firm specializing in rare diseases based in Germany, introduced a new solution called CentoGenome, which leverages whole genome sequencing for diagnosing rare and neurodegenerative diseases. The new CentoGenome employs an advanced next-generation sequencing (NGS)-based assay, offering whole genome sequencing (WGS) tests covering almost all disease-causing variants within a single assay. Besides, it also provides unmatched sensitivity for detecting Copy Number Variations (CNVs) associated to Spinal Muscular Atrophy (SMA), alongside complex disease-causing variations linked to Gaucher Disease (GD) and GBA1-related Parkinson’s Disease (PD) susceptibility. By employing PCR (polymerase chain reaction)-free technology in tricky genomic areas, CentoGenome can significantly reduce bias and deliver high-grade sequencing data, enabling a deeper comprehension of coding, regulatory, and intronic areas.

    Which Companies Are Contributing Significantly To The Rare Disease Diagnostics Market Growth?

    Major companies operating in the rare disease diagnostics market include Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Astellas Pharma Inc., Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BioMarin Pharmaceutical Inc., OPKO Health Inc., Sarepta Therapeutics Inc., Natera Inc., Invitae Corporation, Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., Agios Pharmaceuticals Inc., Orphazyme A/S, RareCyte Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Which Region Holds The Greatest Opportunity For Rare Disease Diagnostics Market Expansion?

    North America was the largest region in the rare disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2025, By The Business Research Company

    Rare Diseases Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Sugar Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-sugar-global-market-report

    Rare Kidney Diseases Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rare Disease Diagnostics Market Forecast: What to Expect by 2029

    Rare Disease Diagnostics Market Forecast: What to Expect by 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Are The Forecasted Market Size Estimates For The Rare Disease Diagnostics Market Between 2025 And 2029?

    The rare disease diagnostics market size has demonstrated robust growth in recent years. It is anticipated to expand from $35.23 billion in 2024 to reach $38.14 billion by 2025, achieving a compound annual growth rate (CAGR) of 8.3%. This historical expansion can be linked to factors such as the increasing demand for cloud-based diagnostics, a greater emphasis on boosting efficiency, the rising prevalence of neurological diseases, an increase in immunological disorders, and higher healthcare expenditures.

    The rare disease diagnostics market size is forecast to undergo substantial growth in the upcoming years, with projections indicating it will reach $56.08 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.1%. This expansion during the forecast period is propelled by factors such as the increasing prevalence of rare diseases, enhanced government initiatives, a rise in the number of hospitals and diagnostic laboratories, the growing incidence of hematology diseases, and an improving healthcare infrastructure. Notable trends expected over this period encompass advancements in genetic testing technologies, the introduction of whole-genome sequencing and next-generation sequencing (NGS), significant investments, and strategic collaborations aimed at research initiatives.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    Which Major Market Drivers Are Shaping The Future Of The Rare Disease Diagnostics Market?

    The growing occurrence of rare diseases is anticipated to boost the expansion of the rare disease diagnostics market moving forward. A rare disease is defined as a health condition with low prevalence, impacting only a small fraction of the population when contrasted with more common illnesses. These diagnostic tools for rare diseases facilitate enhanced disease management, enable the discovery of suitable treatments, and prevent redundant therapies that could lead to severe adverse effects, thus supporting effective treatment. For example, in November 2022, Health Match, a digital health firm based in Australia, reported approximately 150 different rare kidney ailments. These conditions are widespread globally, with an incidence rate of 60–80 incidences per 100,000 people in America and Europe. Consequently, the rising prevalence of rare diseases is fueling the development of the rare disease diagnostics market.

    How Is The Rare Disease Diagnostics Market Classified Into Different Segments?

    The rare disease diagnosticsmarket covered in this report is segmented –

    1) By Test Type: Genetic Test; General Lab Test; Imaging Test

    2) By Technology: Capillary Sequencing; Whole Genome Sequencing; Whole Exome Sequencing; Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample; Buccal Swab Sample; Blood; Saliva

    4) By Disease Type: Gastroenterology Disease; Endocrine And Metabolism Disorders Disease; Hematology And Oncology Disease; Dermatology Disease; Cardiovascular Disorders; Neurology Disease

    5) By End User: Hospital Laboratories; Diagnostics Laboratories; Genetic Testing Laboratories; Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing; Targeted Gene Panels; Exome Sequencing; Carrier Testing

    2) By General Lab Test: Blood Tests; Biochemical Assays; Urine Tests; Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging); CT (Computed Tomography) Scans; Ultrasound; X-Rays

    How Are Emerging Market Trends Shaping The Rare Disease Diagnostics Industry Landscape?

    Technological progress stands out as a significant and growing trend within the rare disease diagnostics market. Leading companies active in the rare disease diagnostics market are embracing novel technologies to maintain their competitive standing. An example of this is Centogene GmbH, a Germany-based rare disease company, which introduced CentoGenome in April 2023. This solution offers whole genome sequencing specifically for diagnosing rare and neurodegenerative conditions. CentoGenome functions as an improved next-generation sequencing (NGS)-based assay, providing whole genome sequencing (WGS) tests for both rare and neurodegenerative disorders. It is designed to identify nearly all relevant disease-causing variants through a single test. Furthermore, it demonstrates optimal sensitivity for identifying Copy Number Variations (CNVs) associated with Spinal Muscular Atrophy (SMA), alongside complex disease-causing variations related to Gaucher Disease (GD) and susceptibility to GBA1-related Parkinson’s Disease (PD). By incorporating PCR (polymerase chain reaction)-free technology in challenging genomic regions, CentoGenome is poised to significantly reduce bias and deliver superior sequencing data, thus enabling a more profound comprehension of coding, regulatory, and intronic areas.

    Who Are The Top Performing Companies In The Rare Disease Diagnostics Market In Recent Years?

    Major companies operating in the rare disease diagnostics market include Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Astellas Pharma Inc., Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BioMarin Pharmaceutical Inc., OPKO Health Inc., Sarepta Therapeutics Inc., Natera Inc., Invitae Corporation, Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., Agios Pharmaceuticals Inc., Orphazyme A/S, RareCyte Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Which Regional Markets Are Contributing Most To The Rare Disease Diagnostics Industry Expansion?

    North America was the largest region in the rare disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Request A Customized Version Of The Rare Disease Diagnostics Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    Browse Through More Reports Similar to the Global Rare Disease Diagnostics Market 2025, By The Business Research Company

    Rare Diseases Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Sugar Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-sugar-global-market-report

    Rare Kidney Diseases Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rare Disease Diagnostics Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

    Rare Disease Diagnostics Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What is the Anticipated CAGR of the Rare Disease Diagnostics Market, and What Factors Will Drive It?

    In the past few years, the size of the rare disease diagnostics market has seen robust growth. Its expansion is set to continue, from $35.23 billion in 2024 to $38.14 billion in 2025, with an 8.3% compound annual growth rate (CAGR). The historical progression is believed to arise from an elevated demand for cloud-based diagnostics, a more significant focus on enhancing efficiency, a growing occurrence of neurological diseases, a rise in immunological disorders, and increased expenditure in healthcare.

    The market for rare disease diagnostics is forecasted to experience swift expansion in the coming years, with projections placing the market size at $56.08 billion in 2029 with a compound annual growth rate (CAGR) of 10.1%. The projected growth in this period is driven by various factors such as the growing prevalence of rare diseases, increased government interventions, an upsurge in the number of hospitals and diagnostic laboratories, the escalation of hematology diseases, and the development of healthcare infrastructure. The upcoming period will likely see major trends like advancements in genetic testing technologies, the roll-out of whole-genome sequencing and next-generation sequencing (NGS), substantial financial investments, and strategic partnerships for research projects.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    What External and Internal Drivers Are Contributing to the Growth of theRare Disease Diagnostics Market?

    The growing prevalence of rare diseases is anticipated to spur the expansion of the rare disease diagnostics market. Rare diseases are defined as health conditions with low frequency that impact a very small segment of the population compared to other more prevalent diseases. Donating diagnosis of such rare diseases facilitates enhanced disease management, determining prospective therapies, and avoiding unneeded treatments which may result in grave side effects, thus forming the basis for effective treatment. For example, as per Health Match, a digital health enterprise based in Australia, in November 2022, there are about 150 different rare kidney disorders, and these afflictions are quite common globally, with incidences ranging from 60–80 per 100,000 people in America and Europe. Consequently, the escalating prevalence of such rare diseases is fuelling the expansion of the rare disease diagnostics market.

    What Segment Types Define the Rare Disease Diagnostics Market Structure?

    The rare disease diagnosticsmarket covered in this report is segmented –

    1) By Test Type: Genetic Test; General Lab Test; Imaging Test

    2) By Technology: Capillary Sequencing; Whole Genome Sequencing; Whole Exome Sequencing; Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample; Buccal Swab Sample; Blood; Saliva

    4) By Disease Type: Gastroenterology Disease; Endocrine And Metabolism Disorders Disease; Hematology And Oncology Disease; Dermatology Disease; Cardiovascular Disorders; Neurology Disease

    5) By End User: Hospital Laboratories; Diagnostics Laboratories; Genetic Testing Laboratories; Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing; Targeted Gene Panels; Exome Sequencing; Carrier Testing

    2) By General Lab Test: Blood Tests; Biochemical Assays; Urine Tests; Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging); CT (Computed Tomography) Scans; Ultrasound; X-Rays

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    Which Geographic Areas Hold the Strongest Growth Potential in the Rare Disease Diagnostics Market?

    North America was the largest region in the rare disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    What Long-Term Trends Are Transforming the Competitive Landscape of the Rare Disease Diagnostics Market?

    The integration of state-of-the-art technology is a leading trend making waves in the rare disease diagnostics market. To maintain their market presence, foremost companies in this sector are harnessing novel technologies. For example, Centogene GmbH, a German firm specializing in rare diseases, introduced CentoGenome, a whole genome sequencing solution to diagnose rare and neurodegenerative diseases, in April 2023. CentoGenome employs an enhanced next-generation sequencing (NGS) assay that provides whole genome sequencing (WGS) tests for a spectrum of rare and neurodegenerative disorders, encompassing nearly all disease-causing variations with a single assay. Additionally, it boasts superior sensitivity for detecting Copy Number Variations (CNVs) related to Spinal Muscular Atrophy (SMA) and complex disease-causing changes associated with Gaucher Disease (GD) and predisposition to GBA1-related Parkinson’s Disease (PD). The application of PCR (polymerase chain reaction)-free technology in hard-to-sequence genomic regions by Centogenome will dramatically decrease bias and provide robust sequencing data, thereby delivering a profound comprehension of coding, regulatory, and intronic regions.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    What Is the Definition of the Rare Disease Diagnostics Market?

    Rare disease diagnostics refers to the process of identifying and diagnosing medical conditions that are considered rare or uncommon. These diagnostics are used for early detection and diagnosis, as well as the selection of targeted and personalized treatment plans for uncommon disorders.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12651

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rare Disease Diagnostics Forecast Report – Designed for Decision Makers and Product Teams

    Rare Disease Diagnostics Forecast Report – Designed for Decision Makers and Product Teams

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Growth Rate of the Rare Disease Diagnostics Market?

    The market size for diagnosing rare diseases has seen robust growth in the past few years. Expected to rise from $35.23 billion in 2024 to $38.22 billion in 2025, it will achieve a compound annual growth rate (CAGR) of 8.5%. The historic growth can be linked to the surge in demand for cloud-based diagnostics, a higher emphasis on enhancing efficiency, growing incidence of neurological disease, an upswing in immunological disorders, and increased healthcare expenditure.

    What Growth Rate Is Forecasted for the Rare Disease Diagnostics Market by 2029?

    The market for diagnosing rare diseases is anticipated to experience significant expansion in the coming years, ballooning to a value of $56.23 billion by 2029, with a compound annual growth rate (CAGR) of 10.1%. The progression during the predicted timeframe can be ascribed to several elements including a rising number of rare disease occurrences, governmental support, the growth of hospitals and diagnostic laboratories, the surge in hematology diseases, and the expanding health care infrastructure. Foreseen trends during this period consist of breakthroughs in genetic testing methods, the launch of whole-genome and next-generation sequencing (NGS), substantial financial inputs, and strategic partnerships geared towards research exploration.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12651&type=smp

    Which Key Companies Are Shaping the Future of the Rare Disease Diagnostics Market?

    Major companies operating in the rare disease diagnostics market include Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Astellas Pharma Inc., Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BioMarin Pharmaceutical Inc., OPKO Health Inc., Sarepta Therapeutics Inc., Natera Inc., Invitae Corporation, Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., Agios Pharmaceuticals Inc., Orphazyme A/S, RareCyte Inc.

    Which Factors Are Driving Demand in the Rare Disease Diagnostics Industry?

    The rare disease diagnostics market is anticipated to expand due to the rising occurrence of rare ailments. These diseases, which are less prevalent compared to other standard illnesses, affect a small fraction of the population. Efficient treatment is enhanced by rare disease diagnostics as they assist in comprehensively managing the disease, pinpointing potential treatment options, and preventing unnecessary treatments that could result in severe side effects. For example, Health Match, a digital health organization based in Australia, reported in November 2022 that there are roughly 150 uncommon kidney diseases. These illnesses are highly prevalent worldwide, with a rate of 60–80 cases per 100,000 individuals in the United States and Europe. As such, the escalating incidence of rare diseases is fuelling the growth of the rare disease diagnostics market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=12651&type=smp

    How Is the Rare Disease Diagnostics Market Segmented by Several Divisions?

    The rare disease diagnostics market covered in this report is segmented –

    1) By Test Type: Genetic Test, General Lab Test, Imaging Test

    2) By Technology: Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays

    3) By Sample Type: Deoxyribonucleic Acid (DNA) Sample, Buccal Swab Sample, Blood, Saliva

    4) By Disease Type: Gastroenterology Disease, Endocrine And Metabolism Disorders Disease, Hematology And Oncology Disease, Dermatology Disease, Cardiovascular Disorders, Neurology Disease

    5) By End User: Hospital Laboratories, Diagnostics Laboratories, Genetic Testing Laboratories, Cancer Research Laboratories

    Subsegments:

    1) By Genetic Test: Whole Genome Sequencing, Targeted Gene Panels, Exome Sequencing, Carrier Testing

    2) By General Lab Test: Blood Tests, Biochemical Assays, Urine Tests, Cytogenetic Tests

    3) By Imaging Test: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scans, Ultrasound, X-Rays

    What are the Emerging Market Trends Driving the Growth of the Rare Disease Diagnostics Industry?

    Innovations in technology are becoming a prominent trend within the rare disease diagnostics market. Major players in the market are adopting these advancements to maintain their market position. For example, Centogene GmbH, a German-based rare disease company, introduced CentoGenome, a whole genome sequencing solution for diagnosing rare and neurodegenerative illnesses, in April 2023. CentoGenome is an improved next-generation sequencing (NGS)-based test that provides whole genome sequencing (WGS) examinations for both rare and neurodegenerative conditions. It can detect almost all disease-triggering variants in one go. Its sensitivity in detecting Copy Number Variations (CNVs) associated with Spinal Muscular Atrophy (SMA), along with complex disease-inducing variations linked with Gaucher Disease (GD) and susceptibility to GBA1-related Parkinson’s Disease (PD), is impeccable. The integration of PCR (polymerase chain reaction)-free technology by CentoGenome in areas of the genome that are difficult to sequence will significantly reduce bias and provide high-quality sequence data. This information will offer deeper insights into coding, regulatory, and intronic regions.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Which Regions Are Driving Growth in the Rare Disease Diagnostics Market?

    North America was the largest region in the rare disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12651

    This Report Delivers Insight On:

    1. How big is the rare disease diagnostics market, and how is it changing globally?

    2. Who are the major companies in the rare disease diagnostics market, and how are they performing?

    3. What are the key opportunities and risks in the rare disease diagnostics market right now?

    4. Which products or customer segments are growing the most in the rare disease diagnostics market?

    5. What factors are helping or slowing down the growth of the rare disease diagnostics market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model